IL-23 inhibitor

This change may make starting Skyrizi more convenient for adults with Crohn's disease by allowing subcutaneous induction at home using an on‑body injector, rather than requiring clinic IV infusions. It also represents an...

A subcutaneous induction option means some adults with moderate–severe Crohn’s disease can begin risankizumab treatment at home rather than needing an IV infusion visit, potentially increasing convenience and access. The...

The updated official label affects dosing options, monitoring, and safety information for guselkumab in people with Crohn’s disease and ulcerative colitis, which can influence treatment decisions and routine testing.

This change may make starting Skyrizi easier and more convenient by allowing induction to be done at home rather than IV infusions in a clinic. It expands options among IL‑23 p19 inhibitors for people with moderate to...

An at‑home subcutaneous induction option for Skyrizi could make starting this IL‑23 inhibitor easier for many adults with moderate‑to‑severe Crohn’s disease, reducing the need for clinic infusions and possibly improving...

Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Risankizumab, IL-23 inhibitor, and Medications.

Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab.

This gives adults with moderately to severely active Crohn’s disease a new at-home way to start Skyrizi treatment instead of needing an IV infusion, which can make initiation more convenient and fit into daily life.

This expands how risankizumab (an IL-23 inhibitor) can be started for adults with moderate-to-severe Crohn’s disease, allowing fully at-home, self-administered induction. That may make initiation easier and reduce clinic...

An FDA approval of a subcutaneous induction option for risankizumab means adults with moderate-to-severe Crohn's disease can start treatment at home using an on-body injector, which may make starting therapy more...

Long-term Phase 3 extension data suggest guselkumab (Tremfya) can sustain clinical and endoscopic remission through three years for some patients with Crohn’s disease.

Reports effectiveness and safety of risankizumab specifically in East Asian participants from global phase 2b/3 UC trials, which may inform regional applicability of trial results for people with moderate-to-severe...

Perianal fistulas are a challenging complication of Crohn’s disease with limited effective options; a phase 3 trial reports that guselkumab improved fistula remission rates through 48 weeks, which could offer a new...

New Phase III data on guselkumab are directly relevant because they report long-term (3-year) maintenance results for Crohn’s disease and one-year fistula outcomes for people with perianal disease — areas that affect...

Cure8 found this source from chicagobusiness.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab. Open the original article for the full...

A new dual-targeting combination (IL-23 + α4β7) showed higher endoscopic remission rates than either drug alone in a Phase IIa Crohn's study, suggesting a potential new approach for patients who need better mucosal...

Cure8 could only read part of this source from finance.yahoo.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab.

Positive Phase 3 pediatric data could expand access to Omvoh for children with ulcerative colitis and change treatment options. That matters to families, clinicians, and patients using or considering biologic therapy.

Narrowing (stenosis) can cause obstructive symptoms and often leads to surgery; evidence that a biologic—guselkumab—may improve non-passable stenosis and reduce fibrosis-associated biology could affect treatment planning...

This mid-stage trial suggests a dual-targeting combo may improve endoscopic remission rates in Crohn’s disease compared with IL-23 inhibition alone, which could influence future treatment options and company strategies...

Perianal fistulas are a common, debilitating complication of Crohn’s disease; longer-term data on treatments that can produce durable fistula remission are directly relevant to patients and clinicians managing this...

These Phase 3 results suggest guselkumab (TREMFYA) may provide durable clinical and endoscopic benefit through three years for adults with moderate to severe Crohn’s disease and may help with perianal fistula...

A combo that adds an α4β7 blocker to an IL-23 inhibitor showed higher endoscopic remission at Week 12 than either drug alone in a phase 2 Crohn’s trial, which could point to a new treatment strategy for people who’ve...

Mid-stage data suggest a dual-targeting approach may improve endoscopic remission for people with moderate–severe Crohn's disease, including many who previously failed advanced therapies. If confirmed in larger trials,...

The report suggests a dual-targeting antibody combination (IL-23 p19 + α4β7) may achieve higher endoscopic remission than either mechanism alone in a treatment-experienced Crohn's population, which could matter for...

Longer-term and real-world data help patients and clinicians understand how well risankizumab and upadacitinib maintain clinical and endoscopic improvement over years of treatment, and early data on an investigational...

Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab. Open the original article for the full details.

Company-reported one-year results suggest mirikizumab (Omvoh), an IL-23p19 inhibitor, can achieve multi-dimensional treatment goals including symptom control, quality-of-life improvement, and steroid-free deep remission...

Deep remission is an emerging treatment target in Crohn’s disease that combines symptoms and objective measures. A meaningful proportion of patients in VIVID-1 achieved corticosteroid-free deep remission with mirikizumab...

Cure8 found this source from streetinsider.com, but the page could not be read reliably yet. It is tagged for Mirikizumab, IL-23 inhibitor, and Research and clinical trials. Open the original article for the full...

Cure8 found this source from fiercepharma.com, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease, Mirikizumab, and IL-23 inhibitor. Open the original article for the full details.

Phase 3 results suggest mirikizumab (Omvoh) can produce sustained, steroid-free remission-related outcomes at one year in both ulcerative colitis and Crohn’s disease, including in some patients who previously failed...

New one-year trial analyses suggest mirikizumab (Omvoh) may help more people with moderate-to-severe ulcerative colitis or Crohn’s disease reach combined clinical and endoscopic goals and reduce steroid dependence.

These results suggest mirikizumab can achieve multiple treatment goals at once — symptoms, objective inflammation measures, and steroid-free status — outcomes that matter to people with IBD because they reflect both...

Patients and clinicians considering long-term use of mirikizumab for Crohn's disease may find evidence here that quality of life and common symptoms (fatigue, abdominal pain, stool frequency) can remain improved out to...

Late-stage (Phase 3) AFFIRM data for subcutaneous Skyrizi in Crohn’s disease are being presented publicly — that could lead to new treatment options if regulators approve expanded indications, and it influences...

Positive phase 3 results for a subcutaneous risankizumab induction regimen may expand access to an IL‑23 p19 therapy option that avoids IV induction and showed strong short-term remission and endoscopic response rates in...

Positive Phase 3 data for Skyrizi in Crohn’s could affect treatment options and access if regulators expand the drug’s label and insurers update coverage; for patients and clinicians it may signal an additional biologic...

Phase III AFFIRM results suggest a subcutaneous risankizumab regimen may increase endoscopic remission in Crohn’s disease, which matters for patients and clinicians weighing biologic options and for regulatory approval...

A Phase 3 positive result for subcutaneous SKYRIZI could expand treatment options for people with Crohn’s disease by offering a more convenient dosing route and may affect how available drugs like Rinvoq are used. It...

The analysis helps compare multiple advanced therapies when head‑to‑head trials are lacking, which may inform drug selection for induction and maintenance in moderate‑to‑severe UC, including for patients who have failed...

New Phase 3 data suggest subcutaneous risankizumab (Skyrizi) can achieve meaningful endoscopic remission and ulcer-free endoscopy rates in adults with active Crohn's disease, including higher responses in patients...

Endoscopic remission (visual healing) is linked to better long-term outcomes in Crohn's disease. An approved subcutaneous induction option could make risankizumab easier to use outside infusion settings.

Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab.

A new subcutaneous option for risankizumab (SKYRIZI) showed higher rates of endoscopic remission and ulcer-free endoscopy versus placebo in a Phase 3 Crohn's disease trial, which could expand at-home biologic options if...

New Phase 3 AFFIRM data for subcutaneous Skyrizi (risankizumab) in Crohn’s disease was released and coincided with a notable AbbVie stock drop, suggesting investor concern about the results.

Perianal fistulizing Crohn's disease causes major quality-of-life problems and is often hard to treat. This trial tests risankizumab in people who did not respond to or could not tolerate other standard therapies, and it...

Long-term Phase 3 extension data suggest guselkumab (Tremfya) may provide sustained clinical and endoscopic remission for some adults with moderate-to-severe Crohn's disease, which could expand treatment options for...